|
C9ORF6 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.69829999951965E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.52320000004858E-07 |
| Normal-vs-Stage2 |
8.42490000000362E-05 |
| Normal-vs-Stage3 |
3.70720000000269E-05 |
| Normal-vs-Stage4 |
4.47079999998934E-06 |
| Stage1-vs-Stage2 |
5.527200E-01 |
| Stage1-vs-Stage3 |
9.499200E-01 |
| Stage1-vs-Stage4 |
5.314800E-01 |
| Stage2-vs-Stage3 |
6.585000E-01 |
| Stage2-vs-Stage4 |
9.964800E-01 |
| Stage3-vs-Stage4 |
6.333600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.72389999842216E-08 |
| Normal-vs-AfricanAmerican |
1.810170E-02 |
| Normal-vs-Asian |
6.206700E-04 |
| Caucasian-vs-AfricanAmerican |
3.697200E-01 |
| Caucasian-vs-Asian |
3.271200E-01 |
| AfricanAmerican-vs-Asian |
8.775400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.43139999997377E-06 |
| Normal-vs-Female |
4.34689999995186E-07 |
| Male-vs-Female |
7.802800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.02609999999659E-07 |
| Normal-vs-Age(41-60Yrs) |
2.09159999999819E-05 |
| Normal-vs-Age(61-80Yrs) |
2.28989999999651E-05 |
| Normal-vs-Age(81-100Yrs) |
2.573400E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.243400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.301200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.509380E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.779400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.860000E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.033600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.297000E-01 |
| Classical-VS-Follicular |
1.438980E-01 |
| Classical-VS-Other |
9.255200E-01 |
| Classical-VS-Normal |
9.13509999866946E-08 |
| Tall-VS-Follicular |
4.013600E-01 |
| Tall-VS-Other |
9.850400E-01 |
| Tall-VS-Normal |
9.178700E-04 |
| Follicular-VS-Other |
4.565400E-01 |
| Follicular-VS-Normal |
3.996900E-03 |
| Other-VS-Normal |
4.459800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.11399999997075E-06 |
| Normal-vs-N1 |
2.18379999999962E-05 |
| N0-vs-N1 |
6.153800E-01 |
|
|
